

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	NeuroScientific Biopharmaceuticals Limited
<b>ABN</b>	13 102 832 995

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Anton Uvarov
<b>Date of last notice</b>	1 August 2018

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Yulia Uvarova (wife) <Techinvest Nominees>
<b>Date of change</b>	06 December 2018
<b>No. of securities held prior to change</b>	<u>Direct:</u> 350,000      Ordinary shares (Escrowed until 27 July 2020)  150,000      Class B Performance Shares 150,000      Class C Performance Shares 150,000      Class D Performance Shares 150,000      Class E Performance Shares  <u>Indirect:</u> 1,275,000      Ordinary shares (1,075,000 escrowed until 27 July 2020)

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Class</b>	<b>Unlisted Options</b>	
<b>Number acquired</b>	Direct :	140,000
	Indirect:	510,000
<b>Number disposed</b>	Direct:	n/a
	Indirect:	n/a
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Direct:	\$1,400
	Indirect:	\$5,100
<b>No. of securities held after change</b>	<u>Direct:</u> 350,000 Ordinary shares (Escrowed until 27 July 2020)  150,000 Class B Performance Shares 150,000 Class C Performance Shares 150,000 Class D Performance Shares 150,000 Class E Performance Shares 140,000 Unlisted Options (exercisable at \$0.20 on or before 7 March 2021)  <u>Indirect:</u> 1,275,000 Ordinary shares (1,075,000 escrowed until 27 July 2020)  510,000 Unlisted Options (exercisable at \$0.20 on or before 7 March 2021)	
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acceptance of non-renounceable entitlement issue	

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	-
---------------------------	---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Nature of interest</b>	-
<b>Name of registered holder (if issued securities)</b>	-
<b>Date of change</b>	-
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	-
<b>Interest acquired</b>	-
<b>Interest disposed</b>	-
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	-
<b>Interest after change</b>	-

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

---

<sup>+</sup> See chapter 19 for defined terms.